In 2014, Malan and coworkers developed a series of polycyclic propargylamine or acetylene derivatives with the aim to synergistically limit apoptotic processes and excitotoxicity, due to aberrant intracellular Ca2+ concentration and oxidative damage deriving from increasing MAO-B activity in AD. The gene discussed is MAOB; the disease is Alzheimer disease.